References
- Casadevall A and Pirofski LA. “The convalescent sera option for
containing COVID-19”. Journal of Clinical Investigation 130 (2020):
1545-1548.
- Wang D., et al. “Clinical characteristics of 138 hospitalized
patients with 2019 novel coronavirus-infected pneumonia in Wuhan,
China”. JAMA 323 (2020): 1061-1069.
- McGonagle D., et al. “Interleukin-6 use in COVID-19 pneumonia related
macrophage activation syndrome”. Autoimmunity Review 19.6 (2020):
102537.
- Carod-Artal FJ (2020) Neurological Complications of Coronavirus and
COVID-19. Rev Neurol 70: 311-322.
- Long B, Brady WJ, Koyfman A, Gottlieb M (2020) Cardiovascular
Complications in COVID-19. Am J Emerg Med S0735-6757(20)30277-1.
- Kyriakidis N, López-Cortés A, González E, Grimaldos A, Prado E.
SARS-CoV-2 vaccines strategies: Acomprehensive review of phase 3
candidates. npj Vaccines. 2021;6(1). Page 6/11.
- Incidence of Bell Palsy in Patients With COVID-19. Akina Tamaki,
MD1,2; Claudia I. Cabrera, MD, MS1,2; Shawn Li, MD1,2; et alCyrus
Rabbani, MD1,2; Jason E. Thuener, MD1,2; Rod P. Rezaee, MD1,2; Nicole
Fowler, MD1, 2.JAMA Otolaryngol HeadNeck Surg. 2021;147(8):767-768.
- Wan EYF Chui CSL Lai FTT et al. Bell’s palsy following vaccination
with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines:
a case series and nested case-control study. Lancet Infect Dis. 2021;
(published online Aug 16.)
https://doi.org/10.1016/S1473-3099(21)00451-5
- Cirillo N Doan R. Bell’s palsy and SARS-CoV-2 vaccines—an unfolding
story. Lancet Infect Dis. 2021; (published online June 7.)https://doi.org/10.1016/S1473-3099(21)00273-5